BlackRock Advisors’s Tvardi Therapeutics TVRD Stock Holding History

BlackRock Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$116K	Hold	347	–	–	﹤0.01%	2974
2016 Q3	$104K	Sell	347 -1,581	-82%	-$343K	﹤0.01%	3002
2016 Q2	$334K	Sell	1,928 -451	-19%	-$98.2K	﹤0.01%	2334
2016 Q1	$533K	Sell	2,379 -3	-0.1%	-$896	﹤0.01%	2042
2015 Q4	$1.45M	Sell	2,382 -60	-2%	-$32.9K	﹤0.01%	1550
2015 Q3	$1.26M	Buy	2,442 +159	+7%	+$106K	﹤0.01%	1554
2015 Q2	$999K	Buy	2,283 +2,205	+2,827%	+$852K	﹤0.01%	1663
2015 Q1	$28K	Buy	78 +15	+24%	+$5.68K	﹤0.01%	3384
2014 Q4	$22K	Hold	63	–	–	﹤0.01%	3485
2014 Q3	$19K	Hold	63	–	–	﹤0.01%	3512
2014 Q2	$38K	Sell	63 -5	-7%	-$2.69K	﹤0.01%	3306
2014 Q1	$46K	Buy	+68	New	+$40.2K	﹤0.01%	3273

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Advisors's TVRD Position: Q4 2016 in Review

BlackRock Advisors held its Tvardi Therapeutics (TVRD) position steady in Q4 2016 at 347 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2974.

BlackRock Advisors first reported a position in TVRD in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.45M in Q4 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

BlackRock Advisors held 347 shares of Tvardi Therapeutics worth $116K as of Q4 2016.
BlackRock Advisors left its Tvardi Therapeutics share count unchanged in Q4 2016.
Tvardi Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2974 holding.
BlackRock Advisors first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Tvardi Therapeutics position peaked at $1.45M in Q4 2015.
101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.